Through a multi-year partnership utilizing its own expertise and Tentatrix’s multifunctional biologics-powered platform, Gilead Sciences A play was recently announced to advance early-stage protein therapies for cancer and inflammation.

The deal immediately unlocks $66 million for Tentatrix in equity funding and upfront payments from Gilead, and a potential payment arrangement of $240 million if Gilead exercises the option to acquire up to three programs from this partnership. does.

Gilead has an advanced drug discovery and commercialization pipeline in areas including HIV, cancer and inflammation, among others. according to a Recent GlobalData report on personalized and precision medicineGilead is one of the leading companies developing personalized therapeutics, largely due to its success in adoptive cell therapies such as Yescarta (exicabtazine xiloleucel), which it absorbed as part of the Kite Therapeutics acquisition. Among personalized treatments, the cell therapy market in particular is expected to flourish in the near future, with revenue projected to generate $52 billion by 2029 – a significant jump from about $3 billion in 2022.

GlobalData’s parent company is pharmaceutical technology,

The Tentatrix deal allows Gilead to expand its strength in protein therapeutics, which don’t have the same logistical and manufacturing challenges as individual cell therapies. The Tentatrix deal isn’t the first protein chemistry research-based deal Gilead has made this year. GlobalData’s deal database, In June, Gilead announced a Collaboration with A-Alpha BioA synthetic biology company that will study protein-protein interactions to inform the development of HIV therapeutics.

Both research-based partnerships allow for upfront and tiered payments based on the success of selected candidate programs.

powered by our signal coverage GlobalData’s Thematic Enginethat tags millions of data items across six alternative datasets – Patents, Jobs, Deals, company filing, mention of social media and news – by topics, sectors and companies. These signals enhance our predictive capabilities, helping us identify the most disruptive threats and the companies best positioned to succeed in each sector we cover.

Leave a Reply

Your email address will not be published. Required fields are marked *